Google in $500 million settlement with DoJ over unlicensed drug ads

26 August 2011

On-line search engine Google Inc has agreed to forfeit $500 million for allowing on-line Canadian pharmacies to place advertisements through its AdWords program targeting consumers in the USA, resulting in the unlawful importation of controlled and non-controlled prescription drugs into the USA, announced Deputy Attorney General James Cole; Peter Neronha, US Attorney for the District of Rhode Island; and Kathleen Martin-Weis, Acting Director of the Food and Drug Administration’s Office of Criminal Investigations.

The forfeiture, one of the largest ever in the USA, represents the gross revenue received by Google as a result of Canadian pharmacies advertising through Google’s AdWords program, plus gross revenue made by Canadian pharmacies from their sales to US consumers.

The shipment of prescription drugs from pharmacies outside the USA to customers in the America typically violates the Federal Food, Drug and Cosmetic Act and in the case of controlled prescription drugs, the Controlled Substances Act. Google was aware as early as 2003 that, generally, it was illegal for pharmacies to ship controlled and non-controlled prescription drugs into the USA from Canada, said the Department of Justice.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics